Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies.
about
Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Addition of suberoylanilide hy ...... ancophone des Myelodysplasies.
@en
Addition of suberoylanilide hydroxamic acid
@nl
type
label
Addition of suberoylanilide hy ...... ancophone des Myelodysplasies.
@en
Addition of suberoylanilide hydroxamic acid
@nl
prefLabel
Addition of suberoylanilide hy ...... ancophone des Myelodysplasies.
@en
Addition of suberoylanilide hydroxamic acid
@nl
P2093
P2860
P50
P356
P1476
Addition of suberoylanilide hy ...... ancophone des Myelodysplasies.
@en
P2093
Eric Wattel
Fatiha Chermat
Groupe Francophone des Myélodysplasies
Jacques Delaunay
Julie Lejeune
Norbert Vey
Pascale Cony-Makhoul
Sophie Dimicoli
Stephan Wickenhauser
Thorsten Braun
P2860
P356
10.1111/BJH.14427
P407
P577
2016-12-15T00:00:00Z